ATE445842T1 - Nachweis spezifischer nitrierter marker - Google Patents

Nachweis spezifischer nitrierter marker

Info

Publication number
ATE445842T1
ATE445842T1 AT03711987T AT03711987T ATE445842T1 AT E445842 T1 ATE445842 T1 AT E445842T1 AT 03711987 T AT03711987 T AT 03711987T AT 03711987 T AT03711987 T AT 03711987T AT E445842 T1 ATE445842 T1 AT E445842T1
Authority
AT
Austria
Prior art keywords
detection
specific
nitrided
markers
oxidative
Prior art date
Application number
AT03711987T
Other languages
English (en)
Inventor
Jean-Yves Reginster
Michelle Deberg
Yves Henrotin
Stephan Christgau
Original Assignee
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liege filed Critical Univ Liege
Application granted granted Critical
Publication of ATE445842T1 publication Critical patent/ATE445842T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/84—Bones; tendons; teeth; cartilage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/173076—Nitrite or nitrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
AT03711987T 2002-03-13 2003-03-12 Nachweis spezifischer nitrierter marker ATE445842T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36392502P 2002-03-13 2002-03-13
DKPA200200381 2002-03-13
PCT/EP2003/002559 WO2003076946A2 (en) 2002-03-13 2003-03-12 Detection of specific nitrated protein markers

Publications (1)

Publication Number Publication Date
ATE445842T1 true ATE445842T1 (de) 2009-10-15

Family

ID=27806430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03711987T ATE445842T1 (de) 2002-03-13 2003-03-12 Nachweis spezifischer nitrierter marker

Country Status (8)

Country Link
US (4) US7393649B2 (de)
EP (1) EP1488240B1 (de)
AT (1) ATE445842T1 (de)
AU (1) AU2003218743A1 (de)
DE (1) DE60329663D1 (de)
DK (1) DK1488240T3 (de)
ES (1) ES2335095T3 (de)
WO (1) WO2003076946A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE445842T1 (de) * 2002-03-13 2009-10-15 Univ Liege Nachweis spezifischer nitrierter marker
US8852879B2 (en) * 2004-04-29 2014-10-07 The Children's Hospital Of Philadelphia Materials and methods for the detection of nitrated fibrinogen
US20050244905A1 (en) * 2004-04-29 2005-11-03 Harry Ischiropoulos Nitrated fibrinogen as a marker for coronary artery disease and rapid blood clot formation
FR2908413B1 (fr) * 2006-11-15 2009-03-06 Synarc Soc Par Actions Simplif Marqueur specifique d'une degradation oxydative de tissus contenant du collagene de type iii,moyens et methodes,kits de diagnostic de suivi ou de pronostic des pathologies ciblees par ce marqueur.
FR2926369A1 (fr) * 2008-01-10 2009-07-17 Univ Joseph Fourier Utilisation d'une proteine ou d'une sequence peptidique nitree pour la mise en oeuvre d'une methode de diagnostic
US10175250B2 (en) * 2012-06-11 2019-01-08 Gabriela Venturini Da Silva Nitrated cardiac troponin I as a biomarker of cardiac ischemia
US9638699B2 (en) 2013-07-18 2017-05-02 The University Of Sydney Biomarkers of oxidative stress
JP2021155362A (ja) * 2020-03-27 2021-10-07 株式会社ナリス化粧品 ペルオキシナイトライト活性阻害方法および、ペルオキシナイトライト活性阻害剤のスクリーニング方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702909A (en) * 1987-11-06 1997-12-30 Washington Research Foundation Methods of detecting collagen type II degradation in vivo
US6132976A (en) * 1992-12-04 2000-10-17 Shriners Hospitals For Children Immunoassays for the measurement of collagen denaturation and cleavage in cartilage
WO1996004311A1 (en) 1994-08-03 1996-02-15 University Of Alabama At Birmingham Research Foundation Monoclonal antibody to nitrotyrosine, methods for diagnosis and methods for treatment of disease
FR2757864B1 (fr) 1996-12-30 1999-03-19 Centre Nat Rech Scient Anticorps reconnaissant specifiquement une proteine nitrosylee, leur procede de preparation, leur utilisation therapeutique et diagnostique
FR2762602B1 (fr) 1997-04-28 1999-06-04 Inst Nat Sante Rech Med Moyens pour la detection precoce de pathologies auto-immunes inflammatoires
GB9928052D0 (en) 1999-11-26 2000-01-26 Osteometer Biotech As Assay of isomerised and/or optically inverted proteins and protein fragments
AU2001259330A1 (en) 2000-05-02 2001-11-12 Mitokor Proteomic determination of protein nitrotyrosine modifications using mass spectrometry
US6812212B2 (en) * 2000-07-28 2004-11-02 Hyesook Kim Assessment of oxidant stress in vitro and in vivo
ATE445842T1 (de) * 2002-03-13 2009-10-15 Univ Liege Nachweis spezifischer nitrierter marker

Also Published As

Publication number Publication date
WO2003076946A2 (en) 2003-09-18
EP1488240A2 (de) 2004-12-22
EP1488240B1 (de) 2009-10-14
US20120010389A1 (en) 2012-01-12
AU2003218743A8 (en) 2003-09-22
DK1488240T3 (da) 2010-03-01
US20050176081A1 (en) 2005-08-11
US7915001B2 (en) 2011-03-29
WO2003076946A3 (en) 2004-03-25
AU2003218743A1 (en) 2003-09-22
US7393649B2 (en) 2008-07-01
DE60329663D1 (de) 2009-11-26
US20110223684A1 (en) 2011-09-15
US20090203040A1 (en) 2009-08-13
US8329874B2 (en) 2012-12-11
ES2335095T3 (es) 2010-03-22

Similar Documents

Publication Publication Date Title
BR0308585A (pt) Anticorpos anti-alfavbeta6
CY1110923T1 (el) Συζυγη που περιλαμβανουν ενα αντισωμα ειδικο για την ed-β περιοχη της ινονεκτινης και η χρηση τους για τον εντοπισμο και την αντιμετωπιση ογκων
CY1108937T1 (el) Χρηση της κινασης πρωτεϊνης ν-β
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
EP1578923A4 (de) Lösliche mic-polypeptide als marker zur diagnose, prognose und behandlung von krebs sowie autoimmunkrankheiten oder -erkrankungen
DE602004019812D1 (de) Marker für neuromyelitis optica
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE60230046D1 (de) Peptide, die atherosklerotische schädigungen binden
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
WO2003058201A3 (en) Methods for identifying marker genes for cancer
HRP20070196T3 (hr) Postupak za pročišćavanje il-18 vezivnog proteina
BR0112644A (pt) Método de identificar marcadores de câncer e usos destes no diagnóstico do câncer
WO2006028429A3 (en) Peptides for targeting the prostate specific membrane antigen
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
DE602004028513D1 (de) Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
ATE336506T1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
EP1558766A4 (de) Verwendung von a33-antigenen und jam-it
ATE445842T1 (de) Nachweis spezifischer nitrierter marker
ATE417930T1 (de) Proteinkinase npk-110
WO2003073818A3 (en) Proteomic analysis of tumors for development of consultative report of therapeutic options
WO2005019475A3 (en) Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties